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An important target in the understanding of the pathogenesis
of acute myeloid leukemias (AML) relies on deciphering the
molecular features of normal and leukemic hemopoietic pro-
genitors. In particular, the analysis of the mechanisms involved
in the regulation of cell proliferation is decisive for the estab-
lishment of new targeted therapies. To gain further insight into
this topic we report herein a novel approach by analyzing the
role of HERG K+ channels in the regulation of hemopoietic cell
proliferation. These channels, encoded by the human ether-a-
go`-go`-related gene (herg), belong to a family of K+ channels,
whose role in oncogenesis has been recently demonstrated.
We report here that herg is switched off in normal peripheral
blood mononuclear cells (PBMNC) as well as in circulating
CD34+ cells, however, it is rapidly turned on in the latter upon
induction of the mitotic cycle. Moreover, herg appears to be
constitutively activated in leukemic cell lines as well as in the
majority of circulating blasts from primary AML. Evidence is
also provided that HERG channel activity regulates cell prolifer-
ation in stimulated CD34+ as well as in blast cells from AML
patients. These results open new perspectives on the patho-
genetic role of HERG K+ channels in leukemias.
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Introduction
The demonstration that acute myeloid leukemia (AML) is a
disease of hemopoietic stem cells has raised fundamental
questions concerning the true target of leukemic transform-
ation in this disease.1 In this light, many studies have been
focused on the identification and characterization of leukemic
progenitor cell populations in patients with AML.2–4 While the
phenotype of leukemic stem cells has been defined,2–7 it is
emerging that primitive AML cells aberrantly express several
set of genes, particularly those involved in the regulation of
cell cycle progression and apoptosis.8,9 Hence, the compari-
son between the pattern of genes expressed in normal vs leu-
kemic progenitors is now regarded as a fundamental topic in
the understanding of the biological features of malignant
transformation leading to AML development.
A novel approach in this field is the study of the expression
of ion channel encoding genes during cell cycle progression.
In fact, recent studies suggested that ion channels, particularly
K+ channels, are important regulators of cell proliferation,10
and it has been hypothesized that the activation of K+ chan-
nels is required for the progression of cells through the G1
phase of the cell cycle.11–15 Moreover, the proliferation of nor-
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mal and tumor cell lines16–22 is often reduced and sometimes
blocked by K+ channel inhibitors. More recently, K+ channel
expression has been linked to the activity of well-known
oncogenes23 and a direct oncogenic potential has been attri-
buted to K+ channel encoding genes.24 A possible link
between K+ channel activity and cell proliferation could be
the clamping of the resting membrane potential (VREST) value,
usually afforded by these types of channels. Oscillations of
VREST in phase with the cell cycle transitions have been
observed in various cell types, and particularly K+-dependent
hyperpolarizations at the G1/S boundary.10 On the other hand,
while terminally differentiated, G0 cells are usually hyperpola-
rized (with VREST between −50 and −70 mV), cycling, and
especially tumor cells tend to be depolarized.27
A contribution to explain this complex pattern came from
our demonstration that, in a set of tumor cells, VREST is often
clamped to almost depolarized values by HERG K+ currents
(IHERG). The human eag-related gene (herg) belongs to an evol-
utionary conserved multigenic family of voltage-activated K+
channels, the eag (ether a-go`-go`) family,26 and encodes for a
channel contributing to the cardiac repolarizing current IKr.27
IHERG besides being a very tiny current, has profound physio-
logical importance: in fact, in the cardiac model IKr regulates
the repolarization phase of the action potential and its alter-
ations lead to dramatic cardiac arrhythmias. Moreover, since
the steady-state conductance of HERG channels is maximal
around −30/−40 mV, IHERG appears to be particularly suitable
to the clamping of VREST around these values in non-excitable
cells, such as neoplastic or immature cells. Indeed, we
showed that both herg and IHERG are preferentially expressed
in tumor cell lines of different histogenesis,28,29 in primary
human endometrial cancers,30 as well as in neuroblasts and
myoblasts only at very early stages of embryo develop-
ment,31,32 and determine the VREST values in these
cells.28,29,33,34 Moreover, the human cell line FLG 29.1
derived from a patient with M5a type leukemia35,36 expresses
herg and a VREST which is governed by a unique K+ current,
namely IHERG, whose biophysical features keep this potential
at strongly depolarized values.37 In these cells IHERG is modu-
lated by integrin activation, and acquires the ability to regulate
gene transcription leading to osteoclastic differentiation; in
these conditions cells stop growing while undergoing a
significant hyperpolarization of the VREST.38
We present here a study on the expression and role of herg
encoded channels in the hemopoietic system in both normal
hemopoietic precursors and leukemic blasts present in AML.
herg expression was first tested in resting peripheral mono-
nuclear cells (PBMNC) obtained from normal donors as well
as in CD34+ collected from peripheral blood (PBCD34+). The
latter are more quiescent than CD34+ cells of different origin
(like cord blood CD34+), but are able to respond to
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cytokine/growth factors stimulation and to enter into the
mitotic cycle more rapidly than other CD34+ cells (eg bone
marrow CD34+ cells).39–41
We report here that both PBMNC and PBCD34+ cells do
not express herg, which is however rapidly up-regulated in
the latter upon induction of proliferation by cytokines/growth
factors. Moreover, this activation turned out to be necessary
for CFU-GM proliferation in vitro. We also report that various
myeloid leukemia cell lines as well as most human AML
express herg and HERG channels in a definite subset of circul-
ating blasts. Evidence is also reported demonstrating that
HERG activity can control leukemia cell proliferation as well
as the clonogenic potential of leukemic blasts present in the
peripheral blood of AML.
On the whole, this study lends support to configuring herg
as a proliferation-related gene, which is rapidly activated dur-
ing cell cycle progression of human hemopoietic progenitors,
while being constitutively expressed in immature leukemic
cells.
Materials and methods
Isolation of peripheral blood mononuclear cells
Peripheral blood samples from 21 healthy donors were sub-
jected to Ficoll–Hypaque (Pharmacia, Uppsala, Sweden)
gradient centrifugation. Mononuclear cells were recovered at
the interphase, washed and counted.
Preparation of CD34+ cells
Mononuclear cells obtained from pooled (4–8) peripheral
blood buffy coats, obtained from blood donors were reco-
vered from a Ficoll–Hypaque gradient, washed and counted.
To select for CD34+ cells, about 108 mononuclear cells were
applied to the Mini Macs column (Miltenyi Biotech, Glad-
bach, Germany), according to the manufacturer’s instructions.
Isolation of leukemic blasts
Leukemic blasts were obtained from the peripheral blood of
46 patients (classified according to the French–American–Bri-
tish committee), treated either at the Hematology Unit of Fir-
enze or at the Department of Internal Medicine of Torino, with
newly diagnosed AML before chemotherapy. Enriched popu-
lations of blast cells (more than 95%) were obtained by Ficoll–
Hypaque (Pharmacia) density gradient centrifugation. In some
cases the cells were cryopreserved and stored in liquid nitro-
gen until use. The frozen AML cells were thawed, washed
with RPMI 1640 medium (Hyclone, Logan, UT, USA), resus-
pended in IMDM (EuroClone Ltd, UK) medium containing 5%
bovine calf serum (BCS) (Hyclone) at the concentration of
2 × 106 /ml and incubated overnight at 37°C. After removal of
clumped cells by sedimentation, the samples had a viability
greater than 90%.
Cytofluorimetric analysis
Samples of 106 cells/ml were stained with propidium iodide
(PI) as described by Vindelov and Christensen.42 The samples
were analyzed using a FACScan flow cytometer (Becton
Dickinson, San Jose´, CA, USA) equipped with a 5 W argon-
ion laser. Histograms of cell number vs linear integrated red
fluorescence were recorded for 50 000 nuclei/sample and
were analyzed using the MultiCycle DNA content and cell
cycle analysis software (Phoenix Flow Systems, San Diego,
CA, USA) to evaluate the distribution in the phases of the
cell cycle.
Cell culture and analysis of cell proliferation
The following leukemia cell lines were analyzed: FLG 29.1,28
K562 (a cell line derived from the acute phase of a chronic
myeloid leukemia43) and HL60 (a promyelocytic cell line44).
Cells were cultured in RPMI with 5% heat-inactivated FCS
(Hyclone Characterized, Logan, UT, USA) and maintained at
37°C in a humidified atmosphere in 5% CO2 in air. For pro-
liferation experiments cells were serum starved for 16 h in
RPMI medium, then seeded in 24-well plates (Corning-Costar,
Corning, NY, USA) at a cell density of 2 × 105 cells per well,
in RPMI containing 1% FCS. When needed HERG channel
blockers (CsCl 5 mM, E4031 40 M and Way 123 398
40 M, final concentrations) were added at time zero. After
24, 48 and 72 h, viable cells (determined by trypan blue
exclusion) were counted in triplicate using a hemocytometer.
Each experimental point represents the mean of four samples
carried out in three separate experiments.
Clonogenic assay
AML blasts were seeded at a density of 1 × 106 in a 1 ml of
mixture containing IMDM, 20% FCS, 10% agar and recombi-
nant cytokines at the following concentrations: IL-3 10 ng/ml,
GM-CSF 20 ng/ml, SCF 50 ng/ml, G-CSF 20 ng/ml. Each sam-
ple was then seeded in triplicate wells of a 24-well microplate
in the absence or in the presence of the specific HERG current
blocker Way 123,398 (200 M, final concentration) and incu-
bated at 37ºC in a humidified atmosphere in 5% CO2 in air.
After 10 days of incubation, all the aggregates containing
more than eight cells were enumerated in each well and the
results averaged.
CFU-GM assay
106 non-adherent mononuclear cells (MNAC) from normal
peripheral blood were seeded as decribed above. Colonies
and clusters were counted after 14 days of incubation.
RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR)
Mononuclear cells were washed twice in ice-cold PBS and
collected by centrifugation. Cells were homogenized in a
guanidinium thiocyanate solution, and total RNA was
extracted according to Cherubini et al.30 RNA purity and
integrity was always checked by running an aliquot on a dena-
turing 1% agarose gel.45 cDNA was then synthesized from 1–
2 g of RNA using 200 U reverse transcriptase SuperScript II
(Invitrogen, Groningen, The Netherlands), plus 200 M each
of dNTP and 2.5 M random hexamers, in a 20 l final reac-
tion volume, for 50 min at 42ºC and 15 min at 70ºC. Two l
of cDNA were then amplified by polymerase chain reaction
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in a 50 l reaction containing Herculase enhanced DNA poly-
merase 2.5 U (Stratagene, La Jolla, CA, USA), 200 M
d(NTP)s, 1× Herculase polymerase reaction buffer. The oli-
gonucleotide primers were as reported in Cherubini et al.30
These primers encompass a nucleotide region from 2171 to
2746 of the human herg cDNA giving rise to a band 575 bp
long. Thirty-five cycles of amplification were carried out after
2 min of enzyme activation at 94°C; denaturation was at 94°C
for 30 s, annealing at 56°C for 1 min, and extention at 72°C
for 1 min. Samples of PCR products were run on a 1.5% aga-
rose gel using a molecular weight marker, the 100 bp DNA
ladder (New England Biolabs, USA) and bands were vis-
ualized by ethidium bromide staining on a UV transillumi-
nator. Control amplifications were performed adding either no
DNA, no RNA and no retrotranscribed RNA in the PCR tube,
but non-specific bands were never observed. cDNA samples
were checked for integrity by PCR detection of human gapdh
using the same conditions described above and using the
same primers as reported in Cherubini et al.30
Immunocytochemistry
Leukemic cells were cytocentrifuged at 300 r.p.m. for 3 min
and fixed in ethanol for 10 min at room temperature, and air
dried before further analysis. Endogenous peroxidase activity
was blocked by incubating the cells with 0.5% H2O2 in water
for 10 min at room temperature. Before proceeding with the
BioGenex Super Sensitive Detection System (BioGenex, San
Ramon, CA, USA), cells were permeabilized with 0.2% Triton
X-100 in Ultra V Block (Lab Vision, Fremont, CA, USA) for
20 min at room temperature. Slides were extensively rinsed
with PBS and then incubated with the anti-HERG primary anti-
body (Alomone Labs, Israel), diluted 1:50 in a solution of 1:10
Ultra V Block/water. The anti-HERG antibody developed in
our laboratory was diluted 1:50 as above. Further incubations
were carried out for 20 min at room temperature: the first one
with the prediluted biotinylated polyvalent anti-goat antibody,
then with the horseradish peroxidase-conjugated streptavidin.
After extensively washing with PBS, color was developed by
incubating the slides with the DAB (3,3′-diamino-benzidine)
chromogen solution for 5–40 min or until acceptable color
intensity had been reached. Slides were then counterstained
with Mayer’s hematoxylin and mounted using Entellan mount-
ing medium. Images were acquired through a Leica photoca-
mera. Magnification was ×40.
Patch-clamp recordings
Cells plated on 35 mm Petri dishes were incubated at 37°C
for appropriate times. Patch-clamp experiments were sub-
sequently performed at room temperature with an amplifier
Axopatch 2-A (Axon Instruments, Foster City, CA,USA). The
whole-cell configuration of the patch-clamp technique46 was
employed using pipettes (borosilicate glass; Hilgenberg,
Germany) whose resistance was in the range 2–3 MΩ. Giga-
seal resistances were in the range 1–10 GΩ. Whole-cell cur-
rents were filtered at 2 KHz. For precise measurement of the
gating parameters of the HERG channels, we carefully com-
pensated pipette and cell capacitance and the series resistance
before each voltage-clamp protocol run. Extracellular sol-
utions were delivered through a nine-hole (0.6 mm), remote-
controlled linear positioner placed near the cell under study.
The standard extracellular solution contained (mM): NaCl
Leukemia
130, KCl 5, CaCl22, MgCl22, Hepes-NaOH 10, glucose 5, pH
7.4. The standard pipette solution at [Ca2+] = 10−7 M con-
tained (mM): K+ aspartate 130, NaCl 10, MgCl22, CaCl24,
EGTA-KOH 10, Hepes KOH 10, pH 7.4. Cells were usually
maintained in our standard solutions, until the whole-cell
mode was obtained. Subsequently, the IHERG was measured at
[K+]o = 40 mM (substituted for NaCl), to magnify the current
amplitude. The cell capacitance was obtained directly by
reading the position of the amplifier knob of the cell capaci-
tance compensation, and its mean value was 7.2 ± 1.2 pF
(n = 22) for FLG cells. Resting potential (VREST) was measured
at 5 mM [K+]o in open circuit conditions. The Vrest value of
cells measured in conditions of active proliferation was
−25 ± 3 mV (n = 22) for FLG 29.1 cells. For data acquisition
and analysis, pClamp software (Axon Instruments) and Origin
(Microcal Software, Northampton, MA, USA) were routinely
used.
Results
Analysis of herg expression
herg expression was studied by RT-PCR in resting mono-
nuclear cells collected from the peripheral blood (PBMNC) of
different blood donors, as well as in the same samples pooled
and enriched in CD34+ cells (PBCD34+). The latter was taken
as representative of resting, G0/G1 hemopoietic progenitors.39
As shown in Table 1 and Figure 1a (lanes 3 and 4) herg RNA
was very rarely detected in PBMNC, while never detected in
seven preparations of PBCD34+. Cytofluorimetric analysis per-
formed on such PBCD34+ confirmed that the great majority
(94.3%) of these cells was in the G0/G1 phase of the cell cycle
(panel b in Figure 1), with only 1.5% in S and 4.1% in the
G2/M phase. However, when PBCD34+ were treated for 12 h
in vitro with IL3, G-CSF and GM-CSF (see Materials and
methods), cells entered the mitotic cycle (see panel c in Figure
1) with 25.3% of cells in S. In these cells herg mRNA
expression was easily detectable (see panel a in Figure 1, lane
5). In contrast, no herg transcription was detected when cells
were treated for shorter times (6 h) or on purified peripheral
lymphocytes after phytohemoagglutinin stimulation (not
shown). Thus, while herg is not transcribed in resting blood
cells, nor in unstimulated CD34+ cells, it is up-regulated as
soon as the latter are induced to enter the proliferative cycle
by cytokine/growth factor stimulation.
Table 1 PCR analysis: number of normal controls and leukemia
patients PCR positive for herg per number of studied subjects, and
their relation to FAB type
PBMNC 2/21
PBCD34+ 0/7
M0 1/2 (50)
M1 6/8 (75)
M2 9/12 (75)
M3 2/2 (100)
M4 12/14 (86)
M5 1/2 (50)
M6 3/3 (100)
M7 2/3 (67)
Total 36 /46 (78)
Values are the number positive/total number, with percentages in
parentheses.
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Figure 1 Expression of herg gene in PBMNC and PBCD34+ cells
and its relation to the cell cycle. (a) RT-PCR relative to herg gene
(upper panel, 575 bp band) and gapdh gene (lower panel, 138 bp
band) in FLG 29.1 (lane 2), PBMNC (lane 3), PBCD34+ (lane 4) and
PBCD34+ treated for 12 h in vitro with IL3, G-CSF and GM-CSF (lane
5). Lane 1: standard 100 bp (New England Biolabs). (b and c) Flow
cytometry histograms of propidium iodide-labelled cells. (b) Resting
PBCD34+ cells; (c) the same PBCD34+ cells after 12 h treatment with
IL3, G-CSF and GM-CSF. Cell cycle analysis was performed as
reported in Materials and methods. A representative experiment is
reported.
Effects of HERG inhibitors on HSC and leukemic cell
proliferation
The above results suggested the possible involvement of herg-
encoded currents in regulating proliferation of hemopoietic
progenitors. To address this question, the clonogenic activity
of CFU-GM present in the PBCD34+ population was then
evaluated in the absence or in the presence of the antiarrhyth-
mic drug Way 123,398, a specific blocker of HERG K+ chan-
nels. As shown in Figure 2, CFU-GM expansion in vitro in
semisolid medium was drastically blocked by Way 123,398.
These results prompted us to investigate whether HERG K+
Figure 2 Effects of HERG inhibitors on colony growth from normal
peripheral blood mononuclear non-adherent cells (MNAC). 106 non-
adherent mononuclear cells (MNAC) from normal peripheral blood
were seeded as described in Materials and methods in the absence
(control) or in the presence of 200 M Way 123,398. Colonies and
clusters (representing CFU-GM) were counted after 14 days of incu-
bation. Values are reported as the number of colonies and clusters
(CFU-GM)/106cells/three wells, and are the average of two individ-
ual experiments.
channels were constitutively expressed in leukemic cells, in
particular in AML, possibly regulating the uncontrolled neo-
plastic growth of these cells. Therefore, the expression of herg
and HERG channels was first studied in myeloid leukemic cell
lines obtained from human AML displaying different pheno-
typic markers. Although at different levels, herg mRNA was
detected by RT-PCR not only in FLG 29.1 cells as previously
reported29 (Figure 3A, lane 2), but also in K562 and HL60 cell
lines (Figure 3A, lanes 3 and 4, respectively). A typical IHERG
could also be detected in both K562 and HL60 cells: an
example, relative to K562 cells, is reported in Figure 3B,
where the biophysical and pharmacological features of IHERG
appear clearly similar to those reported in other tumor cell
lines.29
To assess whether the activity of HERG channels affects the
proliferation of leukemic cell population, as reported in differ-
ent experimental models (see Introduction), the effect of
HERG channels inhibitors (anthiarrhythmic drugs like E4031
and Way 123,398, or CsCl44) on this parameter was evalu-
ated. As shown in Figure 4, when FLG 29.1 leukemia cells
were starved by overnight serum deprivation, their subsequent
proliferation after serum re-addition was inhibited by all the
above mentioned HERG inhibitors, as well as by their combi-
nation. In the latter case, no strong additive effect was
observed, indicating that all the inhibitors affected the same
target, namely HERG currents. Moreover the same inhibitors
did not affect the proliferation of cell lines not expressing IHERG
(Crociani et al, manuscript in preparation). The impairment of
cell proliferation operated by HERG inhibitors is at least in
part related to a retardation of cell cycle progression, as evi-
denced by the increase in the percentage of cells in the G1
phase of the cell cycle observed in FLG 29.1 cells treated with
the combination of HERG inhibitors (inset to Figure 4) after
24 h of incubation in 1% FCS. Substantially similar results
were obtained in K562 (not shown). It is worth noting that in
these experiments no increase in cell death via the apoptotic
pathway was observed after treatment of cells with HERG
inhibitors, either in the cytofluorimetric analysis or performing
the Hoechst test (not shown).
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Figure 3 Expression of herg gene and HERG current in leukemia
cell lines. (A) RT-PCR relative to herg gene (upper panel, 575 bp band)
and gapdh gene (lower panel, 138 bp band) in FLG 29.1 (lane 2),
K562 (lane 3) and HL60 (lane 4) cell lines. Lane 1: standard 100 bp
(New England Biolabs). (B) HERG current traces obtained in K562
cells. IHERG was measured at [K+]o = 40 mM, as the peak current elic-
ited at voltages ranging from +20 to −140 mV, after holding the cell
for 10 s at 0 mV. Upper panel: protocol used in the presented experi-
ment: (a) traces obtained after subtracting from traces in control con-
ditions, traces obtained after perfusion of the cell examined in the
presence of 1 M WAY 123,398 (both traces are reported in (b)).
On the whole, data presented so far suggested that HERG
channels are involved in the regulation of cell cycle
progression of various types of leukemia cell lines.
Expression of herg transcript and protein in primary
AML cells
Experiments were then performed to study herg and HERG
protein expression in primary human AML cells, as well as
their role in leukemia cell proliferation. herg expression was
evaluated by RT-PCR in a set of peripheral blood leukemic
blasts from 46 patients with de novo AML at diagnosis. A rep-
resentative example of a RT-PCR analysis is shown in Figure
5. Table 1 shows the complete results of our analysis and gives
the rates of herg expression according to the FAB type.35 Col-
lectively, herg appears to be expressed in 36/46 (78%) of the
AML examined, with the highest incidence in the M1, M2,
M3 and M4 group; FAB type M2 and M4 accounted for the
majority of the patients examined.
HERG protein expression was also investigated in leukemia
cell lines and some samples of AML with immunocytochemis-
Leukemia
Figure 4 Effect of current inhibitors on proliferation and cell cycle
progression of FLG 29.1 cells. Cell growth of FLG 29.1 in the absence
and in the presence of HERG inhibitors. FLG cells were serum starved
overnight, and then cultured in 1% FCS in the absence (open circles)
or in the presence of 40 M WAY 123,398 (closed circles), 40 M
E4031 (open squares), 5 mM CsCl (closed squares), or a mix of the
three inhibitors (triangles). The high concentrations of HERG inhibitors
were necessary due to the serum binding capacity for various types
of drugs.10 Inset: cell cycle analysis of FLG cells cultured for 24 h in
the absence (white bars) or in the presence of HERG inhibitors (black
bars). Values reported are the percentage of cells in the various phases
of the cell cycle obtained in a representative experiment.
Figure 5 Representative RT-PCR of herg gene in primary AML and
PBMNC from normal blood. RT-PCR relative to herg1 gene (upper
panel, 575 bp band) and gapdh gene (lower panel, 138 bp band) in
FLG29.1(lane 2), patient with AML M2 (lane 3), patient with AML M1
(lane 4), PBMNC from normal donors (lane 5), patient with AML M4
(lane 6). Lane 1: standard 100 bp (New England Biolabs).
try, using the peroxidase method. In Figure 6, photomicro-
graphs of immunocytochemistry of FLG 29.1 cells (panel A)
and of a representative AML patient (panel B) are shown. In
this latter case similar results were obtained both with a com-
mercial anti-HERG antibody and the anti-HERG antibody
developed in our laboratory (inset b), giving the same results.
As evident in Figure 6, while all FLG cells resulted in positive
staining, only some individual cells were positive for HERG
immunostaining in the AML patient. Identical results were
obtained in the other AML samples processed for immunocy-
tochemistry (not shown). The immunocytochemical results
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Figure 6 HERG protein detection in leukemic cell line FLG 29.1 (A) and in primary leukemic cells (B). Cells were immunostained with an
anti-HERG primary antibody (Alomone Labs) directed against the C-terminus of HERG following the protocol reported in Materials and methods;
(inset b) the same primary leukemic cells reported in B were immunostained with an anti-HERG antibody developed in our laboratory20 and
directed against the N-terminus of the same protein; bar 30 m.
suggested that the expression of HERG protein can be easily
detected by this method and that such expression is limited
to definite cell types among the blast cell population.
To test whether HERG channel expression in primary AML
could be involved in the regulation of cell proliferation, as in
the above reported leukemia cell lines, a clonogenic assay
was performed in some of the AML blasts examined in Table
1, in the absence or in the presence of the specific HERG
channel inhibitor Way 123,398. A strong inhibition of colony
formation was observed in almost all cases examined as com-
pared to control, when cells were seeded in semisolid
medium in the presence of Way 123,398 (Figure 7).
Discussion
In this paper we provide evidence that, at variance with
mature PBMNC or resting PBCD34+ cells, growth factor-
stimulated CD34+ cells and AML blasts express the K+ channel
encoding gene herg, and that the progression along the mitotic
Figure 7 Effect of specific HERG channel inhibitors on colony for-
mation from AML peripheral blood. The clonogenic assay was perfor-
med as reported in Materials and methods on AML blasts in the pres-
ence or absence of the HERG current inhibitor Way 123,398 (200 M
final concentation). The use of concentrations of Way 123,398 much
higher than those used in experiments reported in Figure 4 was neces-
sary due to the possible depletion/degradation of the drug over the
large course of experiment. Values are reported as percentage of the
number of colonies detected in treated cultures as compared to con-
trol, untreated cultures. Five different AML cases are reported.
cycle of hemopoietic progenitors cells, either normal or
leukemic, is strongly affected by the activity of HERG K+
channels.
The expression of herg was almost undetectable in PBMNC,
and even in PBCD34+, that are in resting hemopoietic pro-
genitors cells circulating in the bloodstream, but was capable
of undergoing rapid activation of the mitotic cycle upon treat-
ment with a cytokine/growth factor mixture. Indeed, PBCD34+
cells enter into the S phase as soon as 12 h after this treatment,
and rapidly express the herg gene at that time. Many recent
reports demonstrated that definite sets of genes, including
those encoding growth factors and their receptors, cytokines
and relative receptors, as well as transcription factors like c-
myc, c-myb, c-fos and c-jun, are modulated in their transcrip-
tion during response to cytokines/growth factors.48 The results
reported here demonstrate that the herg gene can be included
in the set of genes activated early on during the G0/G1 to S
transition of hemopoietic progenitor cells. It is worth noting
that recent reports demonstrated that inward rectifier K+ (IRK)
channels are up-regulated in cord blood CD34+ cells stimu-
lated to enter cell cycle by a cytokine/growth factors mix.49,50
In particular, the IRK current was detected in resting cord
blood CD34+, and was expressed by a greater percentage of
cells after 16 h incubation with IL3 and stem cell factor (SCF).
We also detected the IRK current encoding gene, Kir 2.1 in
PBCD34+ before cytokine stimulation (data not shown). these
data underline a profound difference between herg and Kir
2.1 genes in that only the former is turned on upon cytokine
stimulation at the onset of cell cycle progression.
Results reported in this study also demonstrate that herg is
expressed in myeloid leukemia cell lines and in the majority
of AML cases studied. Since cells in leukemic lines are ran-
domly distributed throughout the mitotic cycle, it is conceiv-
able that the herg gene is constitutively expressed in these
cells independently of their cell cycle status or any stimu-
lation. By contrast, in AML cases herg is apparently expressed
in a definite set of cells (see immunocytochemical
experiments), consistently with the finding that only a small
proportion of blasts are able to divide, most of them being
terminal cells.51 Many recent reports aimed to define the
characteristics of leukemic progenitor cells present in AML
have shown the constitutive activation of transcription factors
like STATs52 or NF-kB,9 as well as aberrant expression of
tumor suppressor genes IRF1 and DAPK.8,53 Data reported in
this paper indicate the herg gene as the first K+ channel enco-
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ding gene which is constitutively up-regulated in AML blasts,
being completely turned off either in mature myeloid cells and
in resting CD34+ cells.
We also show that HERG channels could be proposed as
regulators of immature hemopoietic cells proliferation. In fact,
the specific block of IHERG in leukemia cell lines always
impaired cell proliferation, irrespective of the drug’s mech-
anism of action,54 while not affecting growth in cell lines not
expressing IHERG. The antiproliferative effect can be accounted
for by an increase in the number of cells present in the G1
phase of the cell cycle. Moreover, we show here that the clon-
ogenic potential of either stimulated CD34+ cells or circulating
blasts of AML can be drastically reduced through specific
HERG channel inhibition.
We have previously shown that HERG channels are linked
to the cell cycle phases in NB cells,28 as well as that a parti-
cular HERG protein isoform is up-regulated in the S phase of
these cells (Crociani et al, manuscript in preparation). In the
present paper we provide strong evidence that HERG channel
activity is necessary for the progression of leukemic cells
beyond the G1/S boundary.
Previous reports indicated K+ channels as important regu-
lators of leukemia cell proliferation, suggesting that the acti-
vation of such channels is a prerequisite for the G1/S pro-
gression of cells.10 The present paper offers a molecular
dimension to this aspect, demonstrating that in activated
PBCD34+ cells, leukemia cell lines and primary AML, cell pro-
liferation is regulated by HERG channels.
Data here reported can also explain the preferential and
constitutive herg expression in tumor cells. In fact, in these
cells the main role of HERG currents could be that of reg-
ulating cell cycle progression, probably by clamping the VREST
values around −30/−40 mV. These are the values often directly
measured in tumor cells,25,28,29,33,34,38 as well as in leukemic
cell lines studied in this paper (see Materials and methods).
The latter could be a threshold value, required for cell sur-
vival, by preventing cells from losing K+ ions, a prerequisite
to enter the apoptotic pathway.55,56 Alternatively, such values
could be apt to maintain, in a properly activated state,57–59
those voltage-dependent proteins involved in cell signalling,
as well as to control the appropriate Ca2+ entry into the cells
through voltage-dependent channels.60
On the whole, based on data reported in this study, we
propose to include K+ channel encoding genes, in particular
the herg gene, among novel molecular markers of hematol-
ogical disorders that are involved in the regulation of hemo-
poietic cell proliferation.
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